Mimulone-induced autophagy through p53-mediated AMPK/mTOR pathway increases caspase-mediated apoptotic cell death in A549 human lung cancer cells

Anticancer properties and mechanisms of mimulone (MML), C-geranylflavonoid isolated from the Paulownia tomentosa fruits, were firstly elucidated in this study. MML prevented cell proliferation in a dose- and time-dependent way and triggered Apoptosis through the extrinsic pathway in A549 human lung adenocarcinoma cells. Furthermore, MML-treated cells displayed autophagic features, such as the formation of autophagic vacuoles, a primary morphological feature of Autophagy, and the accumulation of microtubule-associated protein 1 LIGHT chain 3 (LC3) puncta, another typical maker of Autophagy, as determined by FITC-conjugated immunostaining and monodansylcadaverine (MDC) staining, respectively. The expression levels of LC3-I and LC3-II, specific markers of Autophagy, were also augmented by MML treatment. Autophagy inhibition by 3-methyladenine (3-MA), pharmacological Autophagy Inhibitor, and shRNA knockdown of Beclin-1 reduced apoptotic cell death induced by MML. Autophagic flux was not significantly affected by MML treatment and lysosomal inhibitor, chloroquine (CQ) suppressed MML-induced Autophagy and Apoptosis. MML-induced Autophagy was promoted by decreases in p53 and p-mTOR levels and increase of p-AMPK. Moreover, inhibition of p53 transactivation by pifithrin-α (PFT-α) and knockdown of p53 enhanced induction of Autophagy and finally promoted apoptotic cell death. Overall, the results demonstrate that Autophagy contributes to the cytotoxicity of MML in Cancer cells harboring wild-type p53. This study strongly suggests that MML is a potential candidate for an Anticancer agent targeting both Autophagy and apoptotic cell death in human lung Cancer. Moreover, co-treatment of MML and p53 inhibitor would be more effective in human lung Cancer therapy.